SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-18-007423
Filing Date
2018-09-10
Accepted
2018-09-10 16:03:19
Documents
51
Period of Report
2018-07-31

Document Format Files

Seq Description Document Type Size
1 10-Q bpmx-20180731x10q.htm 10-Q 1617831
2 EX-31.1 bpmx-20180731ex311893013.htm EX-31.1 19286
3 EX-31.2 bpmx-20180731ex3126da8a4.htm EX-31.2 19293
4 EX-32.1 bpmx-20180731ex321c65554.htm EX-32.1 11479
  Complete submission text file 0001558370-18-007423.txt   5383813

Data Files

Seq Description Document Type Size
5 EX-101.INS bpmx-20180731.xml EX-101.INS 1099788
6 EX-101.SCH bpmx-20180731.xsd EX-101.SCH 35160
7 EX-101.CAL bpmx-20180731_cal.xml EX-101.CAL 31754
8 EX-101.DEF bpmx-20180731_def.xml EX-101.DEF 132628
9 EX-101.LAB bpmx-20180731_lab.xml EX-101.LAB 310624
10 EX-101.PRE bpmx-20180731_pre.xml EX-101.PRE 250157
Mailing Address 1505 ADAMS DRIVE, SUITE D MENLO PARK CA 94025
Business Address 1505 ADAMS DRIVE, SUITE D MENLO PARK CA 94025 650-889-5020
BioPharmX Corp (Filer) CIK: 0001504167 (see all company filings)

IRS No.: 593843182 | State of Incorp.: DE | Fiscal Year End: 0131
Type: 10-Q | Act: 34 | File No.: 001-37411 | Film No.: 181062777
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences